Abstract: Use of a component (i) represented by a general formula (I) or a pharmaceutically acceptable salt or isomer of the compound, in combination with a component (ii) of a SGLT2 inhibitor in the manufacture of a medicament for the prevention and/or treatment of diabetes mellitus and/or a diabetic complication, as well as a pharmaceutical composition comprising the component (i) and the component (ii).

Abstract: Provided is an electric switch, including a casing, an actuator, a movable contact frame, a snap-action resilient member, a lock mechanism, a signal switch and a contact switch. The actuator is capable of reciprocating along a first direction. The movable contact frame is provided with a retaining portion. The snap-action resilient member is arranged in the movable contact frame and is compressed by the actuator when the actuator moves. The lock mechanism includes two lock members which are capable of reciprocating in the mounting cavity along a second direction with the movement of the actuator, so as to lock or unlock the retaining portion. A brush of the electric switch is arranged on the movable contact frame. A movable contact of the contact switch is arranged on the movable contact frame.

Abstract: Provided is an electric switch, including a casing, an actuator, a movable contact frame, a snap-action resilient member, a lock mechanism, a signal switch and a contact switch. The actuator is capable of reciprocating along a first direction. The movable contact frame is provided with a retaining portion. The snap-action resilient member is arranged in the movable contact frame and is compressed by the actuator when the actuator moves. The lock mechanism includes two lock members which are capable of reciprocating in the mounting cavity along a second direction with the movement of the actuator, so as to lock or unlock the retaining portion. A brush of the electric switch is arranged on the movable contact frame. A movable contact of the contact switch is arranged on the movable contact frame.